Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Positron Emission Tomography Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA: A Multi-Centre, Blinded Review, Dose Ranging Phase I Study

NCT04839367 is registered in ClinicalTrials.gov with Clarity Pharmaceuticals Ltd as lead sponsor.

NCT NCT04839367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04839367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Positron Emission Tomography Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA: A Multi-Centre, Blinded Review, Dose Ranging Phase I Study
Lead sponsor
Clarity Pharmaceuticals Ltd
Phase
Phase 1
Overall status
Completed
Start date
July 13, 2021
Completion date
October 19, 2022
Enrollment
30 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms